Pendred Syndrome

Article Author:
Linda Garabet Diramerian
Article Editor:
Sehar Ejaz
Updated:
6/30/2020 4:52:46 PM
For CME on this topic:
Pendred Syndrome CME
PubMed Link:
Pendred Syndrome

Introduction

Pendred syndrome characteristically presents with a combination of sensorineural hearing loss and thyroid goiter with or without hypothyroidism. It is an autosomal recessive disorder, which is caused by a biallelic mutation in the PDS gene leading to a defect in pendrin protein.[1]

Etiology

Pendred syndrome occurs due to mutation in The Pendrin Gene (PDS/SLC26A4), which encodes Pendrin/SLC26A4 Protein.[2] SLC26A4 is on chromosome 7q22.3, and it expresses in multiple organs, including the inner ear, kidneys, thyroid, and bronchial epithelial cells.[1][2] It a multifunctional anion exchanger that has an affinity to chloride, iodide, bicarbonate, and other anions.[1]

Epidemiology

The prevalence of Pendred syndrome has been estimated to be between 7.5 and 10 per 100000.[1][3] More importantly, Pendred syndrome accounts for to up to 10% of congenital deafness cases.[2][1] Thus, it may be the most frequent cause of syndromic deafness.[1][4] Given its autosomal recessive mode of inheritance, the risk for inheritance from heterozygous parents is 25%.[1]

Pathophysiology

In the inner ear: Pendrin is expressed in the cochlea and vestibule of the inner ear, thus playing an important role in endolymphatic fluid resorption, acid-base balance, and proper function of the inner ear.[2]

In the thyroid gland: Pendrin is expressed on the thyrocyte apical membrane, where its activity as a Cl-/I- exchanger is essential for cellular iodide efflux into the follicular lumen. A defect in the Pendrin gene usually leads to the partial impairment of thyroid organification. However, patients with Pendred syndrome usually have a euthyroid goiter.[2][1]

In the Kidneys: Pendrin protein is located at or near the apical membrane of type B and non A non B intercalated cells of the cortical collecting ducts.[2] Pendrin acts as chloride/anion exchanger, which leads to bicarbonate secretion to the tubular lumen and chloride reabsorption.[1] Therefore, it plays an important role in the regulation of blood pressure[2]and fluid balance.[2][5] Defect in Pendrin protein can cause metabolic alkalosis.[6]

In Bronchial epithelium: Pendrin is also expressed in the airway epithelium at the apical membrane of bronchial epithelial cells. It helps to regulate airway surface liquid thickness via its function as a Chloride/bicarbonate exchanger. The defective pendrin gene affects mucus production and may play a vital role in patients with asthma and COPD. It also functions as SCN/Cl exchanger helps in the innate defense mechanism of mucosal surfaces by secreting SCN, which is an antioxidant to the lumen.[2]

History and Physical

Hearing Impairment: Pendred syndrome patients have sensorineural hearing loss that is broad and can range from mild to profound.[4] Hearing impairment typically is congenital or prelingual and profound. It can also develop later in infancy with progressive worsening, which may be aggravated by exposure to acoustic traumas, barotraumas, or head injury.[1][4] Hearing impairment is usually bilateral, although asymmetry can be present. Early signs include the absence of a reaction to sound or a delay in language acquisition.

Vestibular manifestations are usually not obvious but maybe noticed during progressive hearing loss period or in performances needing motor skills and balance.[1] Some patients may show features of temporal bone abnormalities.[3]

Thyroid: Euthyroid goiter is the typical presentation of Pendred syndrome.[7] Enlargement of the thyroid gland occurs because of iodide organification defects. It may also present with multinodular goiter in late childhood or early puberty.[1] Some may develop thyroid goiter during their adult life. Approximately 75% of patients with Pendred syndrome have a goiter on physical examination.[7] While the majority of patients present with congenital goiter,[4] the rest can have normal size gland, especially if they have adequate iodine intake.[1][7][4]

Since Iodide organification is not solely dependent on pendrin, patients usually have partial iodide organification defects.[7] While 50 % of patients will have normal thyroid function, others have subclinical hypothyroidism, which can be congenital.[1]

Renal System: Patients with Pendred syndrome might develop life-threatening metabolic alkalosis due to acid-base balance abnormalities.[6]

Evaluation

Genetic testing: 

Molecular genetic testing is the confirmatory test and should be performed to confirm the diagnosis.[1] SLC26A4 gene is the most affected gene, and 50 % of Pendred syndrome patients have a mutation in this gene.[1][3][7] Genetic testing is by direct sequencing of the coding region of the SLC26A4 gene [1] By identifying the biallelic pathogenic variant in the gene or the presence of double heterozygous for one pathogenic variant.[7] FOXII and KCNJI0 gene mutations are affected in less than 2% of patients.[3][7] Because of the diverse mutations in the SLC26A4 gene, researchers have identified approximately 200 sequence variants.[1] Efforts should be made to recognize the full range of presentation of the syndrome to narrow down the suspected cases before performing the molecular studies, taking into account the more specific clinical criteria.[8]

Temporal Bone Findings:

Affected individuals have temporal bone abnormalities, which can be identified by thin-cut CT with detailed cochlear anatomy.

The enlarged vestibular aqueduct is measurable by high-resolution CT of the temporal bone with coronal and axial sections. COnfirmation of vestibular aqueduct enlargement is if the width of the middle portion of the descending limb of the vestibular aqueduct over 1.5 mm.[7][8] Patients also can have cochlear hypoplasia when cochlea have 1.5 turn instead of normal 2.75 turns. If a patient has vestibular aqueduct enlargement associated with cochlear hypoplasia, it is referred to as Mondini malformation.[2][7]

Thyroid Findings: Euthyroid goiter is the typical thyroid abnormality in Pendred syndrome, and it is detected by volumetric studies to assess the size of the gland, thyroid ultrasound helps to evaluate the volume of the thyroid gland and characterize the size and structure of the nodules.[1][7] If Pendred syndrome diagnosis is confirmed, thyroid function tests should take place regularly. Pendred syndrome can also coexist with autoimmune thyroiditis.[1]

Perchlorate test is a screening test for iodide organification defects done by administering radioactive iodine and measuring the intrathyroidal radioactive iodine content. If it is less than 10%, it suggests an organification defect. However, a negative test does not rule out the diagnosis of Pendred syndrome because multiple factors can affect the results. One of the factors is the previous use of high dose iodine intake, which can interfere with the testing.[1][7]

Treatment / Management

  • There is no definite management for Pendred syndrome.
  • The treatment basis is from clinical manifestations. Patients with Pendred syndrome need to follow with a multidisciplinary team, including ENT, endocrinology, genetics, and surgery.
  • Assessment of hearing impairment and treatment accordingly by providing hearing aids and cochlear implants.[7][9]
  • Monitoring thyroid function and thyroid gland size, which might need medical or surgical intervention.[7]
  • The importance of genetic counseling for the family and testing family members and discussion about offspring outcome.[7]

Differential Diagnosis

The differential diagnosis includes other causes of sensorineural hearing loss and thyroid disease.

  • Nonsyndromic causes of congenital deafness such as congenital infections example CMV, exposure to autotoxic agents, or trauma
  • Nonsyndromic enlarged vestibular aqueduct without associated thyroid goiter[7]
  • Congenital hypothyroidism with hearing impairment[7]

Other causes of syndromic deafness examples:

  • Branchiootorenal (BOR) syndrome, branchial cyst, hearing impairment and renal involvement[10]
  • Waardenburg syndrome associated with pigmentation of hair and skin[3]
  • Usher syndrome associated with retinitis pigmentosa[3]
  • Alport syndrome with hearing impairment, with renal and ocular involvement[3]
  • Jervell and Lange-Nielsen and its association with arrhythmia [3]
  • Perrault syndrome characterized by progressives sensorineural hearing loss associated with ovarian involvement in females.[3]

Prognosis

  • Pendred syndrome patients usually have a progressive hearing impairment. Patients with the syndrome can benefit from cochlear implantation, which provides optimal hearing rehabilitation, cochlear implantation in Pendred syndrome can have some surgical difficulties due to the inner ear malformations.[11]
  • Pendred syndrome also affects the thyroid gland and might lead to euthyroid goiter or clinical hypothyroidism.[1]

Complications

  • Progressive hearing impairment
  • Hypothyroidism, euthyroid goiter or thyroid nodules
  • Life-threatening metabolic alkalosis[6]
  • There is a report of a rare case of Hoffmann syndrome with this condition.[12]

Deterrence and Patient Education

  • The importance of follow up for hearing assessment and thyroid monitoring
  • The importance of genetic counseling and testing family members and discussion about offspring outcome.[7]

Enhancing Healthcare Team Outcomes

Patients with Pendred syndrome should be followed by an interprofessional team, including ENT, endocrinology, genetics, and surgery, to provide the follow-up and treatment needed. In surgical cases, surgical nurses can play a significant role by assisting during the procedure, providing post-operative care, and offering patient counsel. Open collaboration is essential to optimize patient outcomes. [Level V]


References

[1] Wémeau JL,Kopp P, Pendred syndrome. Best practice     [PubMed PMID: 28648509]
[2] Rozenfeld J,Efrati E,Adler L,Tal O,Carrithers SL,Alper SL,Zelikovic I, Transcriptional regulation of the pendrin gene. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2011;     [PubMed PMID: 22116353]
[3] Koffler T,Ushakov K,Avraham KB, Genetics of Hearing Loss: Syndromic. Otolaryngologic clinics of North America. 2015 Dec;     [PubMed PMID: 26443487]
[4] Smith N,U-King-Im JM,Karalliedde J, Delayed diagnosis of Pendred syndrome. BMJ case reports. 2016 Sep 12;     [PubMed PMID: 27620717]
[5] Rozenfeld J,Tal O,Kladnitsky O,Adler L,Efrati E,Carrithers SL,Alper SL,Zelikovic I, The pendrin anion exchanger gene is transcriptionally regulated by uroguanylin: a novel enterorenal link. American journal of physiology. Renal physiology. 2012 Mar 1;     [PubMed PMID: 22129966]
[6] Kandasamy N,Fugazzola L,Evans M,Chatterjee K,Karet F, Life-threatening metabolic alkalosis in Pendred syndrome. European journal of endocrinology. 2011 Jul;     [PubMed PMID: 21551164]
[7] Smith RJH, Pendred Syndrome/Nonsyndromic Enlarged Vestibular Aqueduct 1993;     [PubMed PMID: 20301640]
[8] Fugazzola L,Cerutti N,Mannavola D,Crino A,Cassio A,Gasparoni P,Vannucchi G,Beck-Peccoz P, Differential diagnosis between Pendred and pseudo-Pendred syndromes: clinical, radiologic, and molecular studies. Pediatric research. 2002 Apr;     [PubMed PMID: 11919333]
[9] van Nierop JW,Huinck WJ,Pennings RJ,Admiraal RJ,Mylanus EA,Kunst HP, Patients with Pendred syndrome: is cochlear implantation beneficial? Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology     [PubMed PMID: 26331303]
[10] Lindau TA,Cardoso AC,Rossi NF,Giacheti CM, Anatomical Changes and Audiological Profile in Branchio-oto-renal Syndrome: A Literature Review. International archives of otorhinolaryngology. 2014 Jan;     [PubMed PMID: 25992067]
[11] Kontorinis G,Lenarz T,Lesinski-Schiedat A,Neuburger J, Cochlear implantation in Pendred syndrome. Cochlear implants international. 2011 Aug;     [PubMed PMID: 21917203]
[12] Tahir F,Qadar LT,Khan M,Hussain H,Iqbal SU, Hoffmann's Syndrome Secondary to Pendred Syndrome: A Rare Case. Cureus. 2019 Mar 6;     [PubMed PMID: 31106095]